BIOMAT Database Logo BIOMAT Database Logo

DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine. 1979

G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
August 1977, Cancer treatment reports,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
September 1976, Cancer treatment reports,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
January 1986, Medical and pediatric oncology,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
December 1980, Cancer,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
January 1979, Cancer treatment reports,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
January 1977, Cancer,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
May 1989, Cancer,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
January 1977, Cancer,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Results with methyl-CCNU and DTIC in metastatic melanoma.
September 1977, Cancer,
G J Hill, and G E Metter, and E T Krementz, and W S Fletcher, and F M Golomb, and G Ramirez, and T B Grage, and S E Moss
Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma.
November 1992, The British journal of dermatology,
Copied contents to your clipboard!